Vascular disrupting agents in nonsmall cell lung cancer;Vascular disrupting agents beim nicht-kleinzelligen lungenkarzinom

Atemwegs- und Lungenkrankheiten

Volumn 35, Issue 11, 2009, Pages 471-478

  Reinmuth, N ^a   Bischoff, H ^a   Kindermann, M ^a   Steins, M ^a   Thomas, M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Angiogenesis; Blood vessels; Chemotherapy; Non small cell lung cancer

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BEVACIZUMAB; BIBF 1120; CARBOPLATIN; COMBRETASTATIN; COMBRETASTATIN A4; COMBRETASTATIN A4 PHOSPHATE; CYTOTOXIC AGENT; DOCETAXEL; N ACETYLCOLCHINOL PHOSPHATE; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; PACLITAXEL; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; SOBLIDOTIN; VASCULAR TARGETING AGENT; VASCULOTROPIN; VATALANIB; VINBLASTINE; VINCRISTINE; VINFLUNINE;

ABDOMINAL PAIN; ANGINA PECTORIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ATAXIA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CARDIOMYOPATHY; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; DRUG MECHANISM; DYSPNEA; FATIGUE; HEART MUSCLE ISCHEMIA; HUMAN; HYPOKALEMIA; INFECTION; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; NEUROPATHY; PROSTATE CARCINOMA; REVIEW; SARCOMA; SYNCOPE; TACHYCARDIA; THROMBOCYTOPENIA;

EID: 76149110468     PISSN: 03413055     EISSN: None     Source Type: Journal    
DOI: 10.5414/ATP35471     Document Type: Review

References (39)

1. Bennouna J, Delord JP, Campone M, Nguyen L. Vinflunine: a new microtubule inhibitor agent. Clin Cancer Res. 2008; 14: 1625-1632.
2. Bilenker JH, Flaherty KT, Rosen M, Davis L, Gallagher M, Stevenson JP, Sun W, Vaughn D, Giantonio B, Zimmer R, Schnall M, O'Dwyer PJ. Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin Cancer Res. 2005; 11: 1527-1533.
3. Blakey DC,Westwood FR,Walker M, Hughes GD, Davis PD, Ashton SE, Ryan AJ. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res. 2002; 8: 1974-1983.
4. Chaplin DJ, Dougherty GJ.Tumour vasculature as a target for cancer therapy. Br J Cancer. 1999; 80 (Suppl 1): 57-64.
5. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 1997; 57: 1829-1834.
6. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res. 2000; 60: 1388-1393.
7. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003; 9: 669-676.
8. Folkman J. Angiogenesis. Annu Rev Med. 2006; 57: 1-18.
9. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996; 86: 353-364.
10. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100: 57-70.
11. Hande KR, Hagey A, Berlin J, Cai Y, Meek K, Kobayashi H, Lockhart AC, Medina D, Sosman J, Gordon GB, Rothenberg ML. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clin Cancer Res. 2006; 12: 2834-2840.
12. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005; 23: 1011-1027.
13. Hinnen P, Eskens FA. Vascular disrupting agents in clinical development. Br J Cancer. 2007; 96: 1159-1165.
14. Jain RK, Booth MF. What bring pericytes to tumor vessels? J Clin Invest. 2003; 112: 1134-1136.
15. Jassar AS, Suzuki E, Kapoor V, Sun J, Silverberg MB, Cheung L, Burdick MD, Strieter RM, Ching LM, Kaiser LR, Albelda SM. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. Cancer Res. 2005; 65: 11752-11761.
16. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004; 4: 253-265.
17. Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ, Wilson WR. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer. 1998; 78: 439-445.
18. Lin CM, Singh SB, Chu PS, Dempcy RO, Schmidt JM, Pettit GR, Hamel E. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol Pharmacol. 1988; 34: 200-208.
19. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L,Wu Y, Hicklin D, Zhu Z, Hackett NR, Crystal RG, Moore MA, Hajjar KA, Manova K, Benezra R, Rafii S. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med. 2001; 7: 1194-1201.
20. McKeage MJ, Von Pawel J, Reck M, Jameson MB, Rosenthal MA, Sullivan R, Gibbs D, Mainwaring PN, Serke M, Lafitte JJ, Chouaid C, Freitag L, Quoix E. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer. 2008; 99: 2006-2012.
21. Murata R, Siemann DW, Overgaard J, Horsman MR. Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid. Radiat Res. 2001; 156: 503-509.
22. Ozawa Y, Sugi NH, Nagasu T, Owa T,Watanabe T, Koyanagi N, Yoshino H, Kitoh K, Yoshimatsu K. E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo. Eur J Cancer. 2001; 37: 2275-2282.
23. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009; 15: 220-231.
24. Pedley RB, Hill SA, Boxer GM, Flynn AA, Boden R, Watson R, Dearling J, Chaplin DJ, Begent RH. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate. Cancer Res. 2001; 61: 4716-4722.
25. Pruijn FB, van Daalen M, Holford NH, Wilson WR. Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol. 1997; 39: 541-546.
26. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for non-squamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009; 27: 1227-1234.
27. Reinmuth N, Piegelbrock E, Raedel M, Fehrmann N, Hintelmann H, Wagner R, Berdel WE, Thomas M, Freitag L, Mesters RM. Prognostic significance of vessel architecture and vascular stability in non-small cell lung cancer. Lung Cancer. 2007; 55: 53-60.
28. Reinmuth N, Stoeltzing O, Liu W, Ahmad SA, Jung YD, Fan F, Parikh A, Ellis LM. Endothelial survival factors as targets for antineoplastic therapy. Cancer J. 2001; 7 (Suppl 3): S109-119.
29. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355: 2542-2550.
30. Shaked Y, Ciarrocchi A, Franco M, Lee CR,Man S, Cheung AM, Hicklin DJ, Chaplin D, Foster FS, Benezra R, Kerbel RS. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science. 2006; 313: 1785-1787.
31. Shi Q, Rafii S,Wu MH,Wijelath ES, Yu C, Ishida A, Fujita Y, Kothari S, Mohle R, Sauvage LR, Moore MA, Storb RF, Hammond WP. Evidence for circulating bone marrow-derived endothelial cells. Blood. 1998; 92: 362-367.
32. Siemann DW, Shi W. Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res. 2008; 28: 2027-2031.
33. Siim BG, Lee AE, Shalal-Zwain S, Pruijn FB, McKeage MJ, Wilson WR. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol. 2003; 51: 43-52.
34. Thomsen LL, Ching LM, Zhuang L, Gavin JB, Baguley BC. Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice. Cancer Res. 1991; 51: 77-81.
35. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer. 2005; 5: 423-435.
36. Vincent L, Kermani P, Young LM, Cheng J, Zhang F, Shido K, Lam G, Bompais-Vincent H, Zhu Z, Hicklin DJ, Bohlen P, Chaplin DJ, May C, Rafii S. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest. 2005; 115: 2992-3006.
37. Yang AD, Camp ER, Fan F, Shen L, Gray MJ, Liu W, Somcio R, Bauer TW, Wu Y, Hicklin DJ, Ellis LM. Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Res. 2006; 66: 46-51.
38. Yano S, Nishioka Y, Goto H, Sone S. Molecular mechanisms of angiogenesis in non-small cell lung cancer, and therapeutics targeting related molecules. Cancer Sci. 2003; 94: 479-485.
39. Zwi LJ, Baguley BC, Gavin JB,Wilson WR. Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncol Res. 1994; 6: 79-85.